CO4920224A1 - Compuestos de pirrolidinil y pirrolinil etilamina como agonistas kappa - Google Patents

Compuestos de pirrolidinil y pirrolinil etilamina como agonistas kappa

Info

Publication number
CO4920224A1
CO4920224A1 CO97054286A CO97054286A CO4920224A1 CO 4920224 A1 CO4920224 A1 CO 4920224A1 CO 97054286 A CO97054286 A CO 97054286A CO 97054286 A CO97054286 A CO 97054286A CO 4920224 A1 CO4920224 A1 CO 4920224A1
Authority
CO
Colombia
Prior art keywords
optionally substituted
compounds
pirrolinil
pirrolidinil
etilamina
Prior art date
Application number
CO97054286A
Other languages
English (en)
Inventor
Ito Fumitaka
Kondo Hiroshi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CO4920224A1 publication Critical patent/CO4920224A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Mechanical Coupling Of Light Guides (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

Un compuesto de la fórmula: (I) y las sales del mismo, en laque A es halo, hidroxi o similares; la línea de trazos representa un doble enlace opcional, con la condición de que si la línea de trazos es un doble enlace, entonces A está ausente; Ar1 es fenilo opcionalmente sustituido o similares; Ar2 es arilo o heteroarilo seleccionado entre fenilo, naftilo, piridilo y similares, estando el arilo o el heteroarilo opcionalmente sustituido; R1 es hidrógeno, hidroxi, alquilo C1 -C4 o similares; y R2 y R3 se seleccionan, independientemente, entre alquilo C1 -C7 cicloalquilo C3 -C6 , alquenilo C2 -C6 , alquinilo C2 -C6 opcionalmente sustituidos y similares, o R2 y R3 , junto con el átomo de nitrógeno al que están unidos, forman un anillo e pirrolidina, piperidina o morfolina opcionalmente sustituido. Los compuestos son útiles como agonistas kappa.
CO97054286A 1996-09-18 1997-09-17 Compuestos de pirrolidinil y pirrolinil etilamina como agonistas kappa CO4920224A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IBPCT/IB96/00957 1996-09-18

Publications (1)

Publication Number Publication Date
CO4920224A1 true CO4920224A1 (es) 2000-05-29

Family

ID=11004480

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97054286A CO4920224A1 (es) 1996-09-18 1997-09-17 Compuestos de pirrolidinil y pirrolinil etilamina como agonistas kappa

Country Status (38)

Country Link
US (7) US6201007B1 (es)
EP (1) EP0934264B1 (es)
JP (2) JP3195368B2 (es)
KR (1) KR100339666B1 (es)
CN (1) CN1237962A (es)
AP (1) AP1016A (es)
AR (1) AR008168A1 (es)
AT (1) ATE249433T1 (es)
AU (1) AU719895B2 (es)
BG (1) BG64194B1 (es)
BR (1) BR9711506A (es)
CA (1) CA2266006C (es)
CO (1) CO4920224A1 (es)
DE (1) DE69724805T2 (es)
DK (1) DK0934264T3 (es)
DZ (1) DZ2309A1 (es)
EA (1) EA001341B1 (es)
ES (1) ES2205248T3 (es)
HR (1) HRP970509A2 (es)
ID (1) ID19611A (es)
IL (3) IL147368A0 (es)
IS (1) IS4992A (es)
MA (1) MA26441A1 (es)
NO (1) NO313550B1 (es)
NZ (1) NZ334439A (es)
OA (1) OA10996A (es)
PA (1) PA8437201A1 (es)
PE (1) PE109998A1 (es)
PL (1) PL332546A1 (es)
PT (1) PT934264E (es)
SK (1) SK32799A3 (es)
TN (2) TNSN97092A1 (es)
TR (1) TR199900590T2 (es)
TW (1) TW432047B (es)
UA (1) UA60310C2 (es)
WO (1) WO1998012177A1 (es)
YU (1) YU13899A (es)
ZA (1) ZA978358B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051587A1 (fr) 1998-04-01 1999-10-14 Ono Pharmaceutical Co., Ltd. Derives de thiophene condenses et medicaments contenant ceux-ci comme principe actif
IL130429A0 (en) * 1998-08-24 2000-06-01 Pfizer Prod Inc Process for preparing pyrrolidinyl hydroxamic acid compounds
CA2445874A1 (en) 2001-04-30 2002-11-07 Fumitaka Ito Process for preparing hydroxypyrrolidinyl ethylamine compounds useful as kappa agonists
AU2003248351A1 (en) * 2002-02-28 2003-09-09 Pfizer Products Inc. Crystalline anhydrous and monohydrate benzoate salts of (2's,3s)-3-hydroxy-n-{2{n-methyl-n-4-(n-propylamino-carbonyl)phenyl)amino-2-phenyl}-ethylpyrrolidine
AU2003269399A1 (en) * 2002-11-01 2004-05-25 Pfizer Products Inc. Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination
MXPA06011414A (es) * 2004-03-31 2007-04-20 Johnson & Johnson Compuestos heterociclicos sin imidazol como ligandos del receptor de h3 histamina.
US7746514B2 (en) * 2004-04-14 2010-06-29 Hung-Yi Hsu Scanner and exposure control method thereof
US20080058312A1 (en) * 2006-01-11 2008-03-06 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c-Met activity
AU2007256931B2 (en) 2006-05-30 2013-01-24 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine H3 receptor
CN101511807A (zh) * 2006-06-29 2009-08-19 詹森药业有限公司 组胺h3受体的取代的苯甲酰胺调节剂
NZ584998A (en) 2007-11-20 2012-08-31 Janssen Pharmaceutica Nv Cycloalkyloxy-and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8801304D0 (en) * 1988-01-21 1988-02-17 Ici Plc Diamine compounds
DE4034785A1 (de) * 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
DE3935371A1 (de) 1988-12-23 1990-07-05 Merck Patent Gmbh Stickstoffhaltige ringverbindungen
US5232978A (en) * 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
WO1994018165A1 (en) * 1993-02-12 1994-08-18 Pfizer Inc. Sulfonamide compounds as opioid k-receptor agonists
IL117440A0 (en) 1995-03-31 1996-07-23 Pfizer Pyrrolidinyl hydroxamic acid compounds and their production process

Also Published As

Publication number Publication date
US6294569B2 (en) 2001-09-25
CN1237962A (zh) 1999-12-08
PA8437201A1 (es) 1999-12-27
HRP970509A2 (en) 1998-08-31
CA2266006C (en) 2003-11-04
AU719895B2 (en) 2000-05-18
TNSN97092A1 (ar) 1999-12-31
EA001341B1 (ru) 2001-02-26
EP0934264B1 (en) 2003-09-10
IL128959A0 (en) 2000-02-17
PE109998A1 (es) 1999-01-13
DE69724805T2 (de) 2004-07-01
AP1016A (en) 2001-10-08
ZA978358B (en) 1999-03-17
AP9701082A0 (en) 1997-10-31
NZ334439A (en) 2000-09-29
US20010020024A1 (en) 2001-09-06
BR9711506A (pt) 1999-08-24
AU3781297A (en) 1998-04-14
AR008168A1 (es) 1999-12-09
DK0934264T3 (da) 2004-01-26
US6303602B1 (en) 2001-10-16
EP0934264A1 (en) 1999-08-11
IL147368A0 (en) 2002-08-14
ID19611A (id) 1998-07-23
MA26441A1 (fr) 2004-12-20
TNSN97156A1 (fr) 2005-03-15
PL332546A1 (en) 1999-09-13
US20010011091A1 (en) 2001-08-02
TR199900590T2 (xx) 1999-07-21
IS4992A (is) 1999-03-05
YU13899A (sh) 2000-03-21
KR20000036225A (ko) 2000-06-26
CA2266006A1 (en) 1998-03-26
BG103239A (en) 1999-09-30
KR100339666B1 (ko) 2002-06-05
EA199900209A1 (ru) 1999-10-28
US6313302B2 (en) 2001-11-06
US6201007B1 (en) 2001-03-13
JP2001316344A (ja) 2001-11-13
SK32799A3 (en) 2000-09-12
JP2000516634A (ja) 2000-12-12
NO991294D0 (no) 1999-03-17
JP3195368B2 (ja) 2001-08-06
TW432047B (en) 2001-05-01
NO313550B1 (no) 2002-10-21
US20010014683A1 (en) 2001-08-16
NO991294L (no) 1999-03-17
ES2205248T3 (es) 2004-05-01
BG64194B1 (bg) 2004-04-30
PT934264E (pt) 2004-01-30
IL147367A0 (en) 2002-08-14
DZ2309A1 (fr) 2002-12-28
DE69724805D1 (de) 2003-10-16
US20010009921A1 (en) 2001-07-26
US6310061B2 (en) 2001-10-30
WO1998012177A1 (en) 1998-03-26
UA60310C2 (uk) 2003-10-15
ATE249433T1 (de) 2003-09-15
OA10996A (en) 2001-11-06
US20010008890A1 (en) 2001-07-19
US6307061B2 (en) 2001-10-23
US6294557B1 (en) 2001-09-25

Similar Documents

Publication Publication Date Title
ES2509820T3 (es) Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer
ES2193990T3 (es) Derivados de purina.
ES2308299T3 (es) Tiadiazoles como ligandos de receptores de cxc-y cc-quimioquinas.
ES2155995T3 (es) Compuestos de 4-fenilpiperidina.
AR009413A1 (es) Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
YU48390B (sh) Novi derivati 2-anilinopirimidina, postupak za njihovo dobijanje i sredstva za uništavanje štetočina, koja sadrže ove derivate
CO4920224A1 (es) Compuestos de pirrolidinil y pirrolinil etilamina como agonistas kappa
AR062294A1 (es) Derivados de 5,6 -bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii
ES2192183T3 (es) Derivados de imidazopiridina como inhibidores de fosfodiesterasa vii.
ES395714A1 (es) Procedimiento para la obtencion de derivados de piridoqui- nolina.
AR042362A1 (es) Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen
AR125026A1 (es) Inhibidores del sarcómero cardíaco
PT1064281E (pt) Derivados de distamicina benzo-heterociclicos processo para os preparar e a sua utilizacao como agentes antitumorais
ES2191963T3 (es) Derivados triciclicos de triazolobenzazepina, proceso para la obtencion de los mismos y agentes antialergicos.
AR021888A1 (es) Derivados de espiro-benzazepina-piperidina, composiciones farmaceuticas que los comprenden, proceso para preparar dichas composiciones, intermediario util en la preparacion de dichos derivados, procesos para preparar dichos derivados y procesos para preparar dicho intermediario
SE7611137L (sv) 1-bensazolylalkyl-4-substituerade piperidiner
DK1140761T3 (da) Benzophenoner og anvendelse deraf som fotoinitiatorer
AR054414A1 (es) Compuestos espiro-hidantoina sustituidos con piridilo. composiciones farmaceuticas.
AR041720A1 (es) Derivados de n- benzodioxolilo, n- benzodioxanilo y n- benzodioxepinilarilcarboxamida que pueden usarse para el tratamiento de dislipidemia, y composiciones farmaceuticas que los contienen
ECSP972260A (es) Compuestos de pirrolinil etilamina como agonistas kappa
ES2057415T3 (es) Derivados biciclicos.
ECSP024375A (es) Derivados del 2-aminotiazolina y sus uso como inhibidores de no sintetasa
CO4980875A1 (es) Nuevos derivados de la equinocandina, su procedimiento de preparacion y su aplicacion como fungicidas
CO4410199A1 (es) Procedimiento estereoselectivo para producir derivados de dihidro-2,3-benzodiacepina